Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Net Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
Analysis of the solvency ratios reveals a consistent period of deleveraging from early 2022 through the end of 2025, followed by a significant and abrupt increase in leverage in the first quarter of 2026.
- Debt-to-Equity and Capitalization Trends
- A steady decline is observed in the debt-to-equity ratio, which fell from 0.48 in March 2022 to a low of 0.25 by December 2025. Similarly, the debt-to-capital ratio decreased from 0.33 to 0.20 over the same period. This pattern indicates a sustained reduction in reliance on borrowed funds relative to shareholders' equity and total capital.
- Asset Management and Leverage
- The debt-to-assets ratio exhibited a mirrored downward trend, decreasing from 0.23 in March 2022 to 0.15 in December 2025. Concurrently, financial leverage declined from 2.09 to 1.66, suggesting an improvement in the overall solvency profile and a reduced risk associated with the asset-to-equity structure throughout the majority of the analyzed period.
- Interest Coverage and Debt Servicing
- Interest coverage showed higher volatility compared to the leverage ratios. After starting at 18.10 in March 2022, the ratio reached a trough of 10.79 in September 2023 before recovering strongly to 18.17 by December 2025. This indicates that while the margin for debt servicing narrowed mid-period, the ability to cover interest expenses returned to peak levels by the end of 2025.
- Analysis of the March 2026 Pivot
- A sharp reversal in all solvency metrics occurred in March 2026. The debt-to-equity ratio spiked to 0.65, debt-to-capital rose to 0.40, and debt-to-assets increased to 0.31. Financial leverage returned to 2.12, surpassing the peak observed in 2022. This sudden shift suggests a major financing event, such as a substantial debt issuance or a large-scale acquisition, resulting in a rapid increase in long-term obligations.
Debt Ratios
Coverage Ratios
Debt to Equity
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The solvency profile reflects a prolonged period of strategic deleveraging and equity growth followed by a sudden and significant increase in liabilities in the final reported quarter. From March 2022 through December 2025, the capital structure transitioned toward a more conservative position, characterized by falling debt levels and rising shareholder investment.
- Total Debt Trajectory
- Total debt showed a consistent downward trend for the majority of the analyzed period, declining from $17,090 million in March 2022 to $12,929 million by December 2025. This steady reduction in obligations was abruptly reversed in March 2026, where total debt surged to $34,047 million, marking a sharp increase in the company's total liabilities.
- Shareholders' Investment Growth
- Total shareholders' investment exhibited sustained growth, rising from $35,399 million in March 2022 to $52,130 million by December 2025. A notable acceleration in equity accumulation occurred between September 2024 and December 2024, where investment increased by approximately $7.87 billion in a single quarter, contributing to a stronger equity base.
- Debt to Equity Ratio Analysis
- The debt to equity ratio improved steadily from 0.48 in March 2022 to a minimum of 0.25 by December 2025, indicating a reduced reliance on debt financing. This period of increasing solvency was terminated in March 2026, as the ratio spiked to 0.65. This shift indicates a rapid increase in financial leverage, moving the solvency position from a highly conservative state to a significantly more leveraged one.
Debt to Capital
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
From March 2022 through December 2025, a consistent trend of deleveraging is observed. The Debt to Capital ratio experienced a steady decline, moving from a peak of 0.33 in early 2022 to a low of 0.20 by the end of 2025, indicating a strategic reduction in reliance on borrowed funds relative to total capital.
- Total Debt Dynamics
- Total debt decreased progressively from 17,090 million US dollars in March 2022 to 12,929 million US dollars by December 2025. This reduction reflects a sustained decrease in total liabilities over the four-year span.
- Total Capital Growth
- Total capital remained relatively stable between 52,000 and 54,000 million US dollars from 2022 to early 2024, followed by an expansion to 65,059 million US dollars by December 2025. The concurrent decrease in debt and increase in total capital contributed to the systematic compression of the solvency ratio.
- Solvency Ratio Performance
- The Debt to Capital ratio reached its minimum threshold of 0.20 in the latter half of 2025, signaling an improved solvency position and increased financial stability during this period.
A significant shift in the capital structure occurred on March 31, 2026. Total debt surged to 34,047 million US dollars, and total capital rose to 86,108 million US dollars. This resulted in a sharp increase of the Debt to Capital ratio to 0.40, marking the highest level of leverage recorded in the analyzed timeframe. Such a substantial and abrupt increase suggests a major corporate event, potentially a large-scale acquisition or a significant strategic financing initiative.
Debt to Assets
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data indicates a prolonged period of deleveraging and asset growth from early 2022 through late 2025, followed by a significant shift in the capital structure in the first quarter of 2026. For the majority of the analyzed timeframe, the solvency position improved as total debt decreased while total assets generally trended upward.
- Debt Reduction Trend
- Total debt exhibited a steady downward trajectory for most of the period, declining from 17,090 million US$ in March 2022 to a low of 12,929 million US$ by December 2025. This consistent reduction in liabilities suggests a focused effort to lower the company's overall leverage.
- Asset Growth Patterns
- Total assets remained relatively stable between 72,000 and 74,000 million US$ from March 2022 through September 2024. However, a period of accelerated growth began in December 2024, with assets rising to 86,713 million US$ by December 2025, indicating an expansion of the company's resource base.
- Debt to Assets Ratio Analysis
- The debt to assets ratio remained constant at 0.23 for the first several quarters before beginning a gradual decline. The ratio reached its lowest point of 0.15 in the second half of 2025, reflecting a stronger solvency position resulting from the simultaneous decrease in debt and increase in assets.
- Q1 2026 Capital Shift
- A substantial deviation is observed on March 31, 2026, characterized by a sharp increase in both total debt, which rose to 34,047 million US$, and total assets, which climbed to 110,429 million US$. Consequently, the debt to assets ratio increased abruptly to 0.31, marking the highest leverage level recorded in the provided period.
Financial Leverage
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The solvency profile reflects a period of consistent deleveraging followed by a significant shift in capital structure in early 2026. For the majority of the analyzed period, there was a sustained reduction in financial risk as the reliance on debt relative to equity diminished.
- Financial Leverage Trajectory
- A consistent downward trend in financial leverage is observed from March 31, 2022, when the ratio stood at 2.09, reaching a minimum of 1.65 by September 30, 2025. This decline indicates a strengthening of the solvency position and a strategic shift toward a more equity-heavy capital structure over a three-year period.
- Asset and Equity Growth
- Total assets remained relatively stable between 72 billion and 74 billion US dollars from early 2022 through September 2024. However, a notable expansion began in December 2024, with assets increasing to 81.4 billion US dollars and continuing a steep climb to 110.4 billion US dollars by March 31, 2026. Parallel to this, shareholders' investment grew steadily from 35.4 billion US dollars in March 2022 to 52.1 billion US dollars in March 2026, with a significant jump occurring between September and December 2024.
- Capital Structure Shift (Q1 2026)
- A sharp reversal in the deleveraging trend occurred on March 31, 2026, where financial leverage spiked to 2.12. This increase coincides with a substantial surge in total assets, which grew by approximately 28.7 billion US dollars in a single quarter. This pattern suggests a major capital event, such as a large-scale acquisition or significant new debt issuance, which temporarily elevated the financial leverage ratio above the levels seen since early 2022.
Interest Coverage
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Interest coverage
= (EBITQ1 2026
+ EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025)
÷ (Interest expenseQ1 2026
+ Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio exhibits a U-shaped trajectory over the analyzed period, characterized by a significant decline from early 2022 through late 2023, followed by a steady recovery until the end of 2025, before experiencing a sharp contraction in the first quarter of 2026.
- Earnings Before Interest and Tax (EBIT) Trends
- EBIT experienced a sharp decline from 3,007 million USD in March 2022 to a low of 1,474 million USD by December 2022. A gradual recovery ensued, with earnings climbing steadily throughout 2023 and 2024, eventually peaking at 2,478 million USD in December 2025. This upward trend was interrupted in March 2026, when EBIT fell to 1,623 million USD.
- Interest Expense Dynamics
- Interest expenses showed an initial upward trend, reaching a peak of 166 million USD in September 2023. Subsequently, a period of cost reduction was observed throughout 2024 and 2025, with expenses decreasing to 120 million USD by December 2025. A notable spike occurred in March 2026, with expenses rising to 174 million USD, the highest level recorded in the period analyzed.
- Interest Coverage Ratio Analysis
- The interest coverage ratio declined from a high of 20.07 in June 2022 to a minimum of 10.79 by September 2023, reflecting the combined impact of diminishing operating income and rising interest costs. A consistent recovery period followed, with the ratio climbing back to 18.17 by December 2025, driven by the dual effect of expanding EBIT and reduced debt servicing costs. The period concluded with a decline to 16.18 in March 2026, precipitated by the simultaneous drop in earnings and the increase in interest expenses.